Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV

Liver International

Volumn 36, Issue 4, 2016, Pages 515-521

  Saab, Sammy ^a   Gonzalez, Yuri S ^b   Huber, Caroline ^c   Wang, Alice ^b   Juday, Timothy ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ABBVIE INC   (United States)

^c PRECISION HEALTH ECONOMICS   (United States)

Author keywords

Dasabuvir; Hepatic; Ombitasvir; Paritaprevir; Transplantation

Indexed keywords

DASABUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT RECIPIENT; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; LIFESPAN; LIVER GRAFT; MALE; MORBIDITY; MORTALITY; MORTALITY RATE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SENSITIVITY ANALYSIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFECTS; ECONOMIC MODEL; ECONOMICS; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER TRANSPLANTATION; MARKOV CHAIN; MIDDLE AGED; PHENOTYPE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VIRUS ACTIVATION; VIRUS LOAD;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MACROCYCLIC COMPOUNDS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PHENOTYPE; RECURRENCE; RIBAVIRIN; RISK FACTORS; RITONAVIR; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URACIL; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84952673660     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13033     Document Type: Article

References (29)

1. Roche B, Samuel D. Hepatitis C virus treatment pre-and post-liver transplantation. Liver Int 2012; 32: 120-8.
2. Health Resources and Services Administration.Transplant: organ by diagnosis, transplant year (2013-2014). Available at: http://optn.transplant.hrsa.gov/converge/latestData/rptData.asp. Accessed 15 June 2015.
3. Biggins SW, Bambha KM, Terraul TNA, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012; 18: 1471-8.
4. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-41.
5. Coilly A, Roche B, Duclos-Vallée J-C, Samuel D. Management of post transplant hepatitis C in the direct antiviral agents era. Hepatol Int 2015; 9: 192-201.
6. Roche B, Coilly A, Roque-Afonso A-M, Samuel D. Interferon-free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance. Viruses 2015; 7: 5155-68.
7. Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014; 60: 872-84.
8. Coilly A, Roche B, Duclos-Vallée JC, Samuel D. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. Liver Int 2015; 35: 44-50.
9. U.S. Food and Drug Administration. Highlights of prescribing information Viekira Pak. 2014. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed: 18 August 2015.
10. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-82.
11. Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. Transpl Int 2013; 26: 527-34.
12. Arias E. United States life tables, 2010. National Vital Statistics Reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 2014; 63: 1-64.
13. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 150-7.
14. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-38.
15. Red Book. Wholesale acquisition costs. In: Truven Health Analytics. Red Book Online. Greenwood Village, CO. Accessed 23 April 2015.
16. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-71.
17. McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531.
18. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Pharmacoeconomics 1997; 11: 159-68.
19. Brogan AJ, Talbird SE, Thompson JR, et al. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS ONE 2014; 9: e90295.
20. Poordad F, Theodore D, Sullivan J, Grotzinger K. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. J Med Econ 2011; 14: 194-206.
21. Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 335.
22. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
23. Salomon JA, Weinstein M, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronici hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37.
24. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014; 174: 204-12.
25. Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002; 8: 449-57.
26. American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. 2014. Available at: http://www.hcvguidelines.org/full-report-view. Accessed 23 April 2015.
27. Cortesi P, Mantovani L, Ciaccio A, et al. Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis. Am J Transplant 2015; 15: 1817-26.
28. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014; 107: 23-30.
29. Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation [mdash] mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 710-721.